ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation.NPJ vaccines · 2026Review
- Review
- B-EPIC: A Transformer-Based Language Model for Decoding B Cell Immunodominance Patterns.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Vaccine development for pathogens has faced significant challenges, contributing to a public health burden. B-cell epitope (BCE) prediction is a crucial process in vaccine development, but is hindered by limited efficiency and accuracy. To address this, B-Epic, the first pipeline applying Transformer to predict BCEs is independently developed. B-Epic's robustness is validated through multiple testing datasets, including distinguishing clinically-approved vaccine targets, identifying BCEs (the Immune Epitope Database testing dataset; n = 23,888) and immunoreactive peptides (Trypanosoma cruzi peptidome; n = 239,575) with high AUCs of 0.882 and 0.945, respectively, outperforming widely used tools. Based on its superior performance, B-Epic is applied to the prevention of carcinogenic pathogens. In the application to Helicobacter pylori, peptides screened by B-Epic can activate B cells in experiments, suggesting their potential as vaccine targets. In another application to Epstein-Barr virus, B-Epic identifies pan-immunoreactive peptides in a clinical cohort (n = 899). These peptides exhibit higher reactogenicity in nasopharyngeal carcinoma patients than in healthy controls (n = 140), indicating their viability as immunodiagnostic targets. Overall, B-Epic utilizes self-attention, high-dimensional feature projection, and convolutional neural networks to autonomously extract complicated BCE features, enabling accurate BCE prediction and thereby facilitating efforts to prevent infectious diseases and cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.